Infectious Disease
Cellulitis
15
Pipeline Programs↗
4
Active Trials↗
7
Companies Involved↗
Cellulitis is an emerging landscape with 15 programs across 7 companies. The most active players are Eli Lilly, Bayer, Hikma Pharmaceuticals LLC. 9 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
15
clinical trials
Completed7 · 47%
Not yet recruiting2 · 13%
Terminated2 · 13%
Enrolling by invitation1 · 7%
Withdrawn1 · 7%
Recruiting1 · 7%
Other1 · 7%
Clinical Trials
Trial Activity
15 trials
Adjunctive Clindamycin for Cellulitis: C4C Trial.
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 4·NCT01876628·410 enrolled
Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients
Completed·—·N/A·NCT00676130·153 enrolled
Duration of ANtibiotic Therapy for CEllulitis
Terminated·—·Phase 4·NCT02032654·151 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)